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Summary
Background Enteric fever is a serious public health concern in many low-income and middle-income countries. 
Numerous data gaps exist concerning the epidemiology of Salmonella enterica serotype Typhi (S Typhi) and 
Salmonella enterica serotype Paratyphi (S Paratyphi), which are the causative agents of enteric fever. We aimed to 
determine the burden of enteric fever in three urban sites in Africa and Asia.
Methods In this multicentre population-based study, we did a demographic census at three urban sites in Africa 
(Blantyre, Malawi) and Asia (Kathmandu, Nepal and Dhaka, Bangladesh) between June 1, 2016, and Sept 25, 2018. 
Households were selected randomly from the demographic census. Participants from within the geographical census 
area presenting to study health-care facilities were approached for recruitment if they had a history of fever for 72 h 
or more (later changed to >48 h) or temperature of 38·0°C or higher. Facility-based passive surveillance was done 
between Nov 11, 2016, and Dec 31, 2018, with blood-culture collection for febrile illness. We also did a community-
based serological survey to obtain data on Vi-antibody defined infections. We calculated crude incidence for blood-
culture-confirmed S Typhi and S Paratyphi infection, and calculated adjusted incidence and seroincidence of S Typhi 
blood-culture-confirmed infection.
Findings 423 618 individuals were included in the demographic census, contributing 626 219 person-years of observation 
for febrile illness surveillance. 624 S Typhi and 108 S Paratyphi A isolates were collected from the blood of 12 082 febrile 
patients. Multidrug resistance was observed in 44% S Typhi isolates and fluoroquinolone resistance in 61% of S Typhi 
isolates. In Blantyre, the overall crude incidence of blood-culture confirmed S Typhi was 58 cases per 100 000 person-
years of observation (95% CI 48–70); the adjusted incidence was 444 cases per 100 000 person-years of observation 
(95% credible interval [CrI] 347–717). The corresponding rates were 74 (95% CI 62–87) and 1062 (95% CrI 683–1839) in 
Kathmandu, and 161 (95% CI 145–179) and 1135 (95% CrI 898–1480) in Dhaka. S Paratyphi was not found in Blantyre; 
overall crude incidence of blood-culture-confirmed S Paratyphi A infection was 6 cases per 100 000 person-years of 
observation (95% CI 3–11) in Kathmandu and 42 (95% CI 34–52) in Dhaka. Seroconversion rates for S Typhi infection 
per 100 000 person-years estimated from anti-Vi seroconversion episodes in serological surveillance were 2505 episodes 
(95% CI 1605–3727) in Blantyre, 7631 (95% CI 5913–9691) in Kathmandu, and 3256 (95% CI 2432–4270) in Dhaka.
Interpretation High disease incidence and rates of antimicrobial resistance were observed across three different 
transmission settings and thus necessitate multiple intervention strategies to achieve global control of these pathogens.
Funding Wellcome Trust and the Bill & Melinda Gates Foundation.
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Introduction
Enteric fever is estimated to cause 11–18 million infections 
and 100 000–200 000 deaths globally each year, resulting in 
a considerable public health burden in many low-income 
and middle-income countries in Africa and Asia.1,2 The 
human-restricted pathogens Salmonella enterica serovars 
Typhi (S Typhi) and Paratyphi A, B, and C cause enteric 
fever, which presents as a non-specific febrile illness after 
the oral ingestion of contaminated food or water, with a 
reported case fatality rate of around 2·5% despite 
antimicrobial treatment.3 High rates of disease have 
consistently been reported at urban sites in Asia,4 with an 
increasing proportion of S Paratyphi A in some sites.5 In 
Africa, the  cross-continental introduction of the H58 
pathovar from Asia has coincided with a documented 
increase in cases of S Typhi, often associated with large 
outbreaks, persisting for years, at multiple African sites6 
and a concerning increase in antimicrobial resistance.7,8 
The age profile for disease burden differs across different 
epidemiological contexts.4
Various factors lead to underestimation of the true 
incidence of disease, including the non-specific 
presentation of the disease,9 the absence of accurate 
point-of-care diagnostics,10 and the often indiscriminate 
empirical use of antimicrobials for fever syndromes 
without a specific diagnosis in endemic countries.11
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Using data gaps identified through a typhoid trans-
mission model,12 the Strategic Typhoid Alliance across 
Africa and Asia (STRATAA) consortium designed 
a comprehensive study at three sites combining 
household-level and individual-level demographic 
census, health-care utilisation surveys, and enhanced 
facility-based passive surveillance. Community-based 
serological surveys were also done to further characterise 
undiagnosed exposure to the bacteria. Here, we present 
the overall and adjusted incidence of blood-culture-
confirmed S Typhi and S Paratyphi at three urban sites 
in Africa (Blantyre, Malawi) and Asia (Kathmandu, 
Nepal and Dhaka, Bangladesh) and seroconversion rates 
for S Typhi.
Methods
Study design and site selection
The STRATAA programme is a prospective observational, 
population-based collaborative and multidisciplinary 
epidemiological study, comprising health-facility-based 
passive surveillance for febrile illness, community-based 
serological surveys, and health-care utilisation surveys 
nested within a demographic house hold census (figure 1). 
A detailed description of the study sites, design, and 
methods (including sample size con siderations) has 
been previously published.13
Briefly, the study was done in three urban areas 
within the Ndirande township of Blantyre, Malawi, 
the Lalitpur area of Kathmandu, Nepal, and Mirpur, 
Dhaka, Bangladesh. Further information on the study 
sites is provided in the appendix (p 1). Individuals who 
were resident within households inside the demarcated 
geographical area were eligible for inclusion in the 
demographic census, with a household defined as 
individuals living in the same dwelling or compound 
and sharing food from the same kitchen. Approval for 
the joint study protocol was obtained from local research 
ethics committees at all participating centres and the 
Oxford Tropical Research Ethics committee.
Demographic census, census update, and health-care 
utilisation surveys
Within a demarcated geographical area, a baseline 
census population was enumerated over a 3–5-month 
period (June 1–Oct 18, 2016). Consent and demographic 
infor mation were collected from the head of the 
household. Each household and individual were given a 
unique household and member identification number 
and global positioning system (GPS) coordinates were 
recorded. A census update was done three times in 
Dhaka at intervals of 6 months and once in Kathmandu 
at 1 year, and all three sites had a final census at 2 years. 
Research in context
Evidence before this study
We considered evidence from a systematic review of typhoid 
fever incidence studies published in February, 2017, in addition 
to a PubMed search for articles done on Jan 1, 2021, using the 
search terms “(typhoid OR Salmonella Typhi) AND 
seroincidence”. Our search yielded 33 studies from sites in 
21 countries that had reported on the incidence of blood-
culture-confirmed typhoid fever. No population-based 
incidence studies of enteric fever have been done in Malawi or 
Nepal. Two previous studies done in Dhaka, Bangladesh 
reported typhoid fever incidence estimates of 395 cases per 
100 000 person-years for the period 2000–01 and 280 cases 
per 100 000 person-years for the period 2003–04. No previous 
studies have estimated the seroincidence of infection with 
Salmonella enterica serotype Typhi (S Typhi).
Added value of this study
We provide the first population-based enteric fever incidence 
estimates for Blantyre, Malawi and Kathmandu, Nepal, and 
updated estimates of incidence in Dhaka, Bangladesh. This is 
also the first study to compare population-based estimates of 
typhoid fever incidence with estimates of the seroincidence of 
S Typhi infection on the basis of serial anti-Vi IgG titres. 
We found a high incidence of typhoid fever, with overall crude 
and adjusted incidence of blood-culture-confirmed S Typhi per 
100 000 person-years of observation of 58 cases (95% CI 
48–70) and 477 cases (95% credible interval [CrI] 372–770) in 
Blantyre, 74 (95% CI 62–87) and 1065 (95% CrI 687–1824) in 
Kathmandu, and 161 (95% CI 145–179) and 1138 (95% CrI 
889–1477) in Dhaka, respectively. Seroconversion rates for 
S Typhi infection per 100 000 person-years estimated from 
anti-Vi seroconversion episodes in serological surveillance were 
2505 (95% CI 1605–3727) in Blantyre, 7631 (95% CI 
5913–9691) in Kathmandu, and 3256 (95% CI 2432–4270) in 
Dhaka. Additionally, we found high rates of antimicrobial 
resistance across the three sites, with multidrug resistance 
identified in 44% of isolates and fluoroquinolone resistance 
identified in 61% of isolates.
Implications of all the available evidence
The high burden of typhoid fever at these study sites provides 
evidence to support decision making on typhoid conjugate 
vaccine introduction in these countries. Paratyphoid fever is 
rarely observed in sub-Saharan Africa, but accounts for 
5–25% of enteric fever cases in south Asia. Antimicrobial 
resistance is common among isolates of both S Typhi and 
S enterica serotype Paratyphi A, but patterns of resistance vary 
between sub-Saharan Africa and south Asia. Passive 
surveillance of blood-culture-confirmed enteric fever cases 
considerably underestimate the true incidence of the disease. 
Seroincidence data can complement traditional population-
based surveillance of blood-culture-confirmed typhoid fever, 
but further research is needed to interpret the significance of 
increases in anti-Vi titres.
See Online for appendix
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All data were collected through Open Data Kit Collect 
using Android-based tablet devices, and stored on a 
MySQL database.14
Two health-care utilisation surveys were done at 
each site between 2016 and 2018. Approximately 
735 households with children were interviewed per 
survey to estimate the probability that those with fever 
would seek health care at a designated study facility 
(appendix p 6). Households were selected randomly from 
the demographic census.
Passive surveillance
Participants within the demographic census area were 
encouraged to attend study health-care facilities for blood 
culture and treatment if they developed fever. Participants 
presenting from within the geographical census area 
were approached for recruitment if they had a history of 
fever for 72 h or more (later changed to ≥48 h) or current 
temperature of 38·0°C or higher (appendix p 1). 
Serosurveys
Approximately 8500 participants were randomly selected 
in an age-stratified manner from the original demo-
graphic census (appendix p 7). Using GPS or address 
data these individuals were followed up by field teams, 
and paired samples of 1–3 mL of blood were collected 
twice with a 3-month interval.
Microbiological culture of blood was done using 
an automated system (BD BACTEC Blood Culture System 
[Becton-Dickinson, Franklin Lakes, NJ, USA] or BacT/
ALERT [BioMerieux, Marcy-l’Étoile, France]) at all 
three sites following collection of a single aerobic bottle. 
For positive cultures exhibiting growth, organisms 
were then identified using colony morphology, Gram 
staining, standard biochemical tests, and specific antisera, 
with particular focus on the identification of S Typhi, 
S Paratyphi, and non-typhoidal salmonellae.15 Antimicrobial 
susceptibility testing was done using the disc diffusion 
method as per the British Society for Antimicrobial 
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Chemotherapy16 or Clinical and Laboratory Standards 
Institute17 guidelines; antibiotic discs used for the tests 
were obtained from Oxoid (Basingstoke, UK). Further 
details on quality control are included in the appendix 
(p 2).
Anti-Vi IgG titres in plasma collected from participants 
were measured using the commercial VaccZyme ELISA 
kit (The Binding Site, Birmingham, UK) according to the 
manufacturer’s guidelines.
Statistical analysis
We calculated crude incidence rates by dividing the 
number of blood-culture-confirmed cases by the total 
amount of person-time observed in each age group 
and for the entire census population in each site; 
and estimated 95% binomial CIs. To account for the 
underestimation of typhoid fever incidence based on 
culture-confirmed cases, we adjusted the observed crude 
incidence rates of S Typhi for blood-culture sensitivity, 
the probability of receiving a blood culture diagnostic 
test, and the probability of health-care-seeking using a 
Bayesian framework that incorporated both observed 
STRATAA data and information from the literature. 
Adjustments factors were site-specific and varied by age 
group.18 We calculated median values and 95% Bayesian 
credible intervals for the adjusted incidence estimates 
(appendix p 2).
We defined seroconversion as a 2-fold increase in 
anti-Vi IgG titres and an absolute titre of 50 EU/mL 
or higher at the second timepoint to account for 
small variations above the lower limit of detection; the 
absolute titre threshold was based on baseline data 
from presumably unexposed participants in a human 
challenge model.19 We divided the number of participants 
with an increase in antibody titre that met the definition 
for seroconversion by the total person-time in each age 
group, only including participants with two blood tests 
done approximately 3 months apart. Person-time was 
determined by multiplying the number of participants 
in each age group by the mean time between visits 
(in years) for the entire cohort to give an estimate of 
seroincidence per 100 000 person-years of observation. 
We estimated 95% binomial CIs.
Role of the funding source
The study funders had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
423 618 individuals residing in 99 033 households were 
included in the demographic censuses, contributing 
626 219 person-years of observation for febrile illness 
surveillance (199 634 in Blantyre, 203 614 in Kathmandu, 
222 971 in Dhaka; appendix p 7).
During the 2-year period of passive surveillance, 
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Blantyre, n=2473 in Kathmandu, and n=6015 in Dhaka) 
were enrolled from ten health-care facilities (two in 
Blantyre, two in Kathmandu, and six in Dhaka). Baseline 
characteristics for febrile patients are described in table 1.
Pathogenic bacteria were isolated from the blood 
cultures of 822 (6·8%) of 12 082 participants: 162 (4·5%) 
in Blantyre, 166 (6·9%) in Kathmandu, and 494 (9·2%) in 
Dhaka. The most common bacteria were S Typhi 
(624 [76·2%] of 822 isolates; 115 in Blantyre, 150 in 
Kathmandu, and 359 in Dhaka), S Paratyphi A (108 isolates 
[13·0%] of 822 isolates; 13 in Kathmandu, 95 in Dhaka), 
and Salmonella enterica serovar Typhimurium 
(S Typhimurium; 16 [1·9%] of 822 isolates in Blantyre). 
Blood-culture positivity rates for typhoidal pathogens 
(S Typhi and S Paratyphi A and B) were 3·2% in Blantyre, 
6·6% in Kathmandu, and 8·2% in Dhaka. The overall 
contamination rate was 7·9% (322 [9·0%] in Blantyre, 
56 [2·3%] in Kathmandu, and 574 [9·5%] in Dhaka).
The incidence of hospital admission for typhoid fever 
was higher in Blantyre (eight [7·9%] hospital admissions 
among 105 cases) than in Kathmandu (five hospital 
admissions [3·3%] among 150 cases) and Dhaka (ten 
hospital admissions [2·5%] among 359 cases), and 
deaths secondary to typhoid infection were only reported 
in Blantyre (two deaths [1·9%] among 105 cases). 
Previous antimicrobial usage and prescription of anti-
microbials following blood-culture collection was 
significantly higher in blood-culture positive individuals 
than blood-culture negative indi viduals across all three 
sites (table 1).
The crude incidence of blood-culture-confirmed 
S Typhi infection was 58 cases (95% CI 48–70) per 100 000 
person-years of observation in Blantyre, 74 cases (62–87) 
per 100 000 person-years of observation in Kathmandu, 
and 161 cases (145–179) per 100 000 person-years of 
observation in Dhaka (table 2). Age-stratified unadjusted 
incidence for S Typhi was highest among individuals 
aged 5–9 years at all three sites (table 2); in Dhaka, the 
incidence rates for individuals aged 4 and 5 years 
was higher than the other sites (643 cases [424–936] per 
100 000 person-years of observation and 620 cases 
[405–908] per 100 000 person-years of observation, 
respectively; appendix p 11).
S Paratyphi was not identified in Blantyre; overall crude 
incidence of blood-culture-confirmed S Paratyphi A 
infection was 6 cases (95% CI 3–10) per 100 000 person-
years of observation in Kathmandu and 42 cases (34–52) 
per 100 000 person-years of observation in Dhaka, with 
the highest incidence identified among individuals aged 
5–9-years.
In Blantyre, the incidence of Salmonella Typhimurium 
(causing invasive non-typhoidal Salmonella disease) 
was highest among individuals aged 2 years (124 cases 
[45–269] per 100 000 person-years of observation; 
appendix p 11). S Typhi was isolated from children 
younger than 2 years at all sites (appendix p 11).

























0–4 years 83 (53–124) 632 (398–965) 7·6 72 (33–136) 764 (307–1921) 10·7 417 (337–511) 2625 (1764–4244) 6·3
5–9 years 146 (103–201) 861 (599–1203) 5·9 341 (250–455) 6713 (3085–18 730) 19·7 554 (456–666) 3228 (2276–4757) 5·8
10–14 years 88 (56–132) 602 (377–915) 6·9 191 (128–275) 3750 (1653–10 559) 19·6 268 (203–348) 1564 (1050–2384) 5·8
15–29 years 32 (20–48) 361 (219–567) 11·4 92 (71–119) 1457 (684–3918) 15·8 98 (76–124) 956 (603–1635) 9·8
≥30 years 21 (10–37) 248 (124–447) 12·0 6 (2–13) 92 (29–301) 15·0 29 (19–42) 279 (157–514) 9·7
All ages 58 (48–70) 444 (347–717) 7·7 74 (62–87) 1062 (683–1839) 14·4 161 (145–179) 1135 (898–1480) 7·0
Rates are per 100 000 person-years of observation. CrI=credible interval. *Adjusted for blood-culture sensitivity, probability of receiving a blood culture diagnostic test, and probability of health-care seeking.
Table 2: Incidence of blood-culture-confirmed typhoid fever by site and age 



























Adjusted for blood-culture sensitivity alone
Adjusted for blood-culture sensitivity and probability 
of receiving a blood-culture diagnostic test
Adjusted for blood-culture sensitivity, probability of 
receiving a blood culture diagnostic test, and health-care 
seeking
Figure 2: Crude observed incidence and adjusted incidence of typhoid fever caused by 
Salmonella enterica serotype Typhi across the three study sites
CrI=credible interval. 
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The adjusted incidence of typhoid fever was highest 
among individuals aged 5–9-years at all three sites (table 2, 
figure 2). The largest adjustments at each site were 
for the the probability of being enrolled and receiving a 
blood culture in Blantyre (2·9-fold increase) and for the 
probability of seeking health care in Kathmandu (6·7-fold 
increase) and Dhaka (3·7-fold increase; table 2, figure 2).18
The antimicrobial susceptibility profiles for both S Typhi 
and S Paratyphi A differed at each site (appendix p 9). 
Fluoroquinolone non-susceptibility was common among 
S Typhi isolates in Dhaka (355 [99%] of 359 isolates) and 
Kathmandu (127 [83%] of 153 isolates), but was only 
identified in a single isolate from Blantyre (one [<1%] 
of 115 isolates). Fluoroquinolone non-susceptibility 
was almost universal among S Paratyphi A isolates 
(14 [100%] of 14 isolates in Kathmandu, 94 [>99%] of 
95 isolates in Dhaka). In contrast, 92% of S Typhi isolates 
from Blantyre were multidrug resistant (resistant to 
ampicillin, chloram phenicol, and cotrimoxazole), whereas 
only 1% of isolates in Kathmandu and 39% of isolates 
in Dhaka were multidrug resistant. Azithromycin non-
susceptibility was detected in both Asian sites but was not 
assessed in Blantyre. Azithromycin non-susceptibility was 
more frequent in S Paratyphi A (four [30%] of 14 isolates 
in Kathmandu, 41 [43%] of 95 isolates in Dhaka) than 
S Typhi (ten [7%] of 150 isolates in Kathmandu, 
11 [3%] of 359 isolates in Dhaka).
The seroconversion data showed different rates of 
presumed exposure to and infection with S Typhi in the 
three sites (figure 3; appendix p 15). Overall seroincidence 
was highest in Kathmandu (7631 episodes [95% CI 
5913–9691] per 100 000 person-years of observation), was 
more than seven times higher than the estimated 
adjusted incidence, and more than 100 times higher than 
the observed blood-culture-confirmed incidence. The 
seroincidence in Blantyre (2505 episodes [1605–3727] per 
100 000 person-years of observation) was five times 
higher than the adjusted incidence and 43 times higher 
than the observed incidence, and the seroincidence in 
Dhaka (3256 episodes [2432–4270] per 100 000 person-
years of observation) was 2·5 times higher than the 
adjusted incidence and 20 times higher than the observed 
incidence (figure 3).
Similar to the incidence estimates from passive 
surveillance, the seroincidence analysis showed that 
exposure was highest among the youngest age groups 
(figure 3). The seroincidence estimates for Dhaka among 
indiv iduals aged 0–4-years mirrored the passive 
surveillance estimates in which incidence was highest 
among individuals aged 4 years. At all sites, but 
particularly in Kathmandu, high rates of seroconversion 
were observed in the older age groups (age >30 years), in 
contrast with the lower age-specific incidence rates 
captured from passive surveillance.
Discussion
In this STRATAA surveillance study, S Typhi was the 
primary cause of bacterial bloodstream infection in 
people with fever across three different epidemiological 
contexts in Africa and Asia. Crude incidence of blood-
culture-confirmed disease identified through passive 
surveillance were adjusted to estimate the incidence of 
typhoid fever occurring within the census populations 
using parameters measured from within the populations, 
indicating that true rates are likely to be considerably 
higher than those estimated directly by blood culture. 
Seroincidence data indicate that exposure to S Typhi 
might be even higher, suggesting substantial numbers of 
subclinical episodes, which might make an important 
contribution to transmission in the population.12
In Dhaka, previous crude incidence estimates 
from population-based studies have ranged from 200 to 
390 cases per 100 000 person-years of observation20 for 
all age groups, with the highest crude incidence rates 
(of up to 1870 per 100 000 person-years of observation) 
recorded in children younger than 5 years.21 The Global 
Burden of Disease Study 2017 estimated an adjusted 
incidence of 641 cases per 100 000 person-years of 
observation in Bangladesh, reduced from 1459 per 
100 000 person-years of observation in 1990.2 In this 
study, the observed incidence (161 cases per 
100 000 person-years of observation) and adjusted 
incidence (1135 per 100 000 person-years of observation) 
for all age groups were consistent with these previous 
estimates and suggest that typhoid fever incidence 
might not be declining as quickly as previously 
estimated.2 Adjusted incidence of S Typhi was as high as 
3228 cases per 100 000 person-years of observation in 
the 5-9-year age group with the highest single-year 
incidence among individuals aged 4 years.
Figure 3: Seroincidence estimates of Salmonella enterica serotype Typhi exposure
Seroincidence was calculated based on data from the serological survey, with randomly selected participants 
sampled approximately 3 months apart. Seroconversion was defined as a 2-fold rise increase in anti-Vi IgG titres and 
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A hospital-based study from Kathmandu estimated 
overall crude S Typhi incidence to be 59 cases per 
100 000 person-years of observation, averaged over a 
4-year period, with a mean age of disease at 16 years.22 
Although this estimate is similar to our observed 
incidence of 74 cases per 100 000 person-years of 
observation, our surveillance suggests that this is likely to 
be a substantial underestimate, with adjusted incidence 
of 1062 cases per 100 000 person-years of observation. 
In Kathmandu, the proportion of participants using 
alternative health-care facilities and private pharmacies 
was high, particularly among the 5–9-year age group, 
leading to a large increase in the adjusted incidence rate 
when compared with the crude rate. Similar to estimates 
for Dhaka, the highest observed and adjusted incidence 
was observed among the 5–9-year age group; however, 
these estimates also had the greatest degree of uncertainty 
due to the infrequent use of study facilities.
Disease incidence estimates for Africa have 
a greater level of uncertainty than estimates from Asia 
due to fewer population-based studies. A meta-analysis 
estimated adjusted rates of 620 cases per 100 000 person-
years of observation for eastern sub-Saharan Africa and 
1459 cases per 100 000 person-years of observation for 
central sub-Saharan Africa, although the estimates had 
wide CIs.1 In Malawi, since 2010, an increase in the 
number of S Typhi cases reported from central hospitals 
has been observed, with a minimum adjusted incidence 
estimate (accounting only for blood-culture sensitivity) 
of 207 cases per 100 000 person-years of observation at 
the peak of the typhoid fever outbreak in 2013 in 
Blantyre.23 Our results detail the ongoing high incidence 
of disease in Blantyre (adjusted incidence 444 cases per 
100 000 person-years of observation).
The surveillance data were consistent with other 
published data on the increasing importance of 
S Paratyphi A in both Dhaka (117 cases per 100 000 person-
years of observation) and Kathmandu (37 cases per 
100 000 person-years of observation)5,24 in the 5–9-year age 
group. In Blantyre, no cases of S Paratyphi A were 
identified, but consistent with surveillance across Africa,6 
a considerable burden of S Typhimurium remains in 
the youngest children (observed incidence 117 cases 
per 100 000 person-years of observation among children 
aged 2 years).
Salmonellae are on the WHO priority pathogen list due 
to the high rate of associated antimicrobial resistance 
and the risk this confers to human health.25 Data from 
STRATAA surveillance are consistent with published 
meta-analyses on the increase in antimicrobial resistance 
among typhoidal Salmonellae and the different anti-
microbial resistance profiles of S Typhi and S Paratyphi A, 
and differences in antimicrobial resistance between Africa 
and Asia.26 Isolates from Blantyre were almost entirely 
multidrug resistant, with one case of fluoroquinolone 
non-susceptibility documented during the surveillance 
period. Since STRATAA was completed, additional isolates 
with fluoroquinolone non-susceptibility have been 
detected in Blantyre (unpublished data). By contrast, in 
Dhaka and Kathmandu, high rates of fluoroquinolone 
non-susceptibility and docu mented azithromycin non-
susceptibility were observed. These data, combined with 
data from passive surveillance showing individuals who 
were S Typhi culture positive had substantially higher 
rates of antibiotic use before seeking health care and 
higher rates of antibiotic prescription at the time of heath-
care facility visit, demonstrate the escalating risk of 
antimicrobial resistance associated with global typhoid 
management.
Our findings demonstrate that adjustment factors 
cannot be applied universally to observed rates of blood-
culture-confirmed disease across different epidemio-
logical contexts and age groups. Use of alternative 
health-care facilities and pharmacies was higher at Asian 
sites than the African site, leading to higher inflation of 
incidence once adjusted, whereas in Blantyre, fewer 
individuals who sought health care at study facilities 
received a blood culture due to high incidence of febrile 
illness, inadequate health-care infrastructure, and 
parental refusal.18
In Blantyre, individuals with typhoid presented with 
more severe fever and a longer duration of fever, and 
hospitalisation was two times higher than at the other 
two sites. This difference might indicate that despite 
the adjustments for sampling and health-care seeking 
behaviour, undetected mild or subclinical disease remains 
an ongoing burden, consistent with the comparatively 
high rates of seroconversion observed at the Blantyre site. 
Such differences might also reflect differences in the 
immunological history of individuals across the three 
sites.
Measuring seroincidence, as described in this study, 
provides an alternative estimate of the rate of exposure 
to S Typhi than provided by passive blood-culture 
surveillance. A cross-sectional seroepidemiological 
study from Fiji estimated seroprevalence of anti-Vi IgG 
antibodies to be higher than predicted based on blood-
culture-confirmed disease.27 A cross-sectional serological 
study in Kathmandu showed that titres of anti-Vi IgG 
were highest in the 16–55-year age group, consistent 
with our data.28
This study is the first to use serological data to calculate 
seroincidence for S Typhi across multiple sites. With the 
exception of the 10–14-year age group in Dhaka, all the 
age-specific seroincidence estimates either exceeded or 
had overlapping CIs with the adjusted incidence esti-
mates from passive surveillance, such that seroincidence 
could be used as an upper bound for disease incidence 
within certain populations.
Quantifying the incidence of subclinical infections is 
also key to understanding the contribution of different 
age groups to the transmission of S Typhi. The high rates 
of seroconversion among older individuals, particularly 
in Nepal, could be evidence of ongoing exposure and 
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transmission within these age groups, which due to the 
high use of antimicrobials from community pharmacies, 
or partial immunity leading to subclinical infection, 
rarely requires hospital care.
A marked difference was observed between the 
seroincidence estimates and the adjusted incidence 
estimates from passive surveillance across the three 
sites, with higher seroincidence rates in Kathmandu 
compared with Dhaka, in contrast to what was observed 
in passive surveillance. No established cutoff exists to 
define seroconversion, and anti-Vi antibody might not be 
the most accurate method of calculating seroincidence. 
Further work examining different typhoid antigens 
is ongoing.
This study has a number of limitations. First, due to the 
very large number of individuals attending health-care 
facilities, particularly in Blantyre, it was not possible to 
enrol all eligible participants. Second, due to the high 
number of private health-care facilities and pharmacies in 
both Dhaka and Kathmandu, our surveillance sites only 
captured a proportion of all febrile illnesses. Third, blood-
culture sensitivity is only around 60% and is affected by 
previous antimicrobial use, volume of blood collected, and 
timing of blood collection in the natural history of 
infection. Sensitivity of blood culture is also affected by 
the contamination rate at collection, which was higher in 
Blantyre and Dhaka. Low sensitivity of blood culture is 
likely to result in underestimation of incidence based on 
blood-culture-confirmed cases, but we accounted for these 
factors in the adjusted estimates. Fourth, to encourage 
higher usage of study facilities, free treatment and care 
was provided within the census populations by study 
teams, to a variable extent at different sites. With improved 
diagnosis through the use of blood culture and appropriate 
prescription of antimicrobials, the hospital admission and 
complication rate might have been falsely lowered 
compared with other previously published observational 
data.2,3,23 Fifth, during the surveillance period, a proportion 
of the children from within these populations were 
enrolled into a typhoid conjugate vaccine trial, which 
might have introduced a degree of direct and indirect 
protection to the communities.29 Individuals who were 
eligible for vaccination in the trial were not included in the 
seroincidence analysis, which reduced the numbers 
of participants with paired samples, particularly in 
Kathmandu. The use of anti-Vi IgG seroconversion as an 
indicator of exposure to S Typhi infection is sensitive to 
the thresholds used to define seroconversion, which are 
based on scarce data. It is also possible that exposure to 
non-typhoidal organisms (eg, Citrobacter) could elicit 
these antibodies. Sixth, surveillance sites were chosen in 
urban areas with known high enteric fever incidence, and 
the geographical footprint and duration of surveil lance 
was restricted. These factors together might reduce the 
generalisability of these data to other sites.
Despite these limitations in the design of this 
study, nesting multiple surveillance methods within a 
demographic census allowed the weaknesses of individual 
methods to be contextualised in different settings, and 
varying populations to be characterised.
Our data support the WHO recommendation for 
introduction of typhoid conjugate vaccines for children 
from age 6 months. Catch-up campaigns are also likely to 
be cost-effective,30 and should be implemented among 
children up to age 15 years. Our seroincidence data also 
suggest ongoing transmission into adulthood, which 
would support the use of catch-up campaigns to reduce 
transmission and the incidence of disease throughout 
the entire population. Our data support modelling work 
showing the impact vaccine catch-up campaigns could 
have on local disease incidence.30 The introduction 
of typhoid conjugate vaccines into these sites while 
preventing disease and reducing the high incidence 
identified through STRATAA, should also have an impact 
on overall antimicrobial use and potentially rates of 
resistance. High incidence of enteric fever necessitates 
multiple intervention strategies to achieve global control 
of these pathogens through development of water and 
sanitation infrastructure, the introduction of efficacious 
typhoid conjugate vaccines, and the development of 
vaccines for S Paratyphi A.
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